{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:04:21Z","timestamp":1790129061050,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e01033","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:23:40Z","timestamp":1786022620000},"page":"e01033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study)"],"prefix":"10.1016","volume":"23","author":[{"given":"Brooke A.","family":"Keating","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Ogru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Isikgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"El-Sukkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-019-0138-4","article-title":"Autism spectrum disorder","volume":"6","author":"Lord","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41398-023-02374-w","article-title":"Comorbidities in autism spectrum disorder and their etiologies","volume":"13","author":"Khachadourian","year":"2023","journal-title":"Transl Psychiatry"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01033_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106552","article-title":"The cost of autism spectrum disorders","volume":"9","author":"Horlin","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01033_bib4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.neuron.2015.09.016","article-title":"Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci","volume":"87","author":"Sanders","year":"2015","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01033_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","article-title":"Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism","volume":"180","author":"Satterstrom","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01033_bib6","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molmed.2024.06.004","article-title":"Targeting epigenetic dysregulation in autism spectrum disorders","volume":"30","author":"Herrera","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neurot.2026.e01033_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13229-017-0121-4","article-title":"Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses","volume":"8","author":"Modabbernia","year":"2017","journal-title":"Mol Autism"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/aur.1427","article-title":"Longitudinal volumetric brain changes in autism spectrum disorder ages 6\u201335 years","volume":"8","author":"Lange","year":"2015","journal-title":"Autism Res"},{"key":"10.1016\/j.neurot.2026.e01033_bib9","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009886","article-title":"Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities","volume":"4","author":"Zoghbi","year":"2012","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.neurot.2026.e01033_bib10","series-title":"Autism spectrum disorders: etiology and pathology. BTI - autism spectrum disorders","first-page":"1","author":"Sauer","year":"2021"},{"key":"10.1016\/j.neurot.2026.e01033_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.crvi.2016.05.004","article-title":"Current knowledge on the genetics of autism and propositions for future research","volume":"339","author":"Bourgeron","year":"2016","journal-title":"C R Biol"},{"key":"10.1016\/j.neurot.2026.e01033_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-genom-091212-153431","article-title":"The genetic landscapes of autism spectrum disorders","volume":"14","author":"Huguet","year":"2013","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10.1016\/j.neurot.2026.e01033_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.neuron.2019.02.041","article-title":"A synaptic perspective of fragile X syndrome and autism spectrum disorders","volume":"101","author":"Bagni","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2026.e01033_bib14","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1002\/mco2.497","article-title":"Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy","volume":"5","author":"Zhuang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.neurot.2026.e01033_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-021-00530-8","article-title":"Maternal immune activation and neuroinflammation in human neurodevelopmental disorders","volume":"17","author":"Han","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40001-024-01916-2","article-title":"New advances in the diagnosis and treatment of autism spectrum disorders","volume":"29","author":"Qin","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.neurot.2026.e01033_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatr Hum Dev"},{"key":"10.1016\/j.neurot.2026.e01033_bib18","article-title":"Olanzapine, risperidone, and aripiprazole use in children and adolescents with autism spectrum disorders","volume":"72","author":"Hesapcioglu","year":"2020","journal-title":"Research autism Spectr Disord"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12888-021-03151-z","article-title":"Diagnosis despite clinical ambiguity: physicians' perspectives on the rise in autism spectrum disorder incidence","volume":"21","author":"Davidovitch","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.rasd.2010.06.004","article-title":"The increasing prevalence of autism spectrum disorders","volume":"5","author":"Matson","year":"2011","journal-title":"Research autism Spectr Disord"},{"key":"10.1016\/j.neurot.2026.e01033_bib21","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"Pharmacy and therapeutics"},{"key":"10.1016\/j.neurot.2026.e01033_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence","volume":"16","author":"Arnold","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.neurot.2026.e01033_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/molecules29020410","article-title":"The neurotherapeutic arsenal in cannabis sativa: insights into anti-neuroinflammatory and neuroprotective activity and potential entourage effects","volume":"29","author":"Al-Khazaleh","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.neurot.2026.e01033_bib24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3390\/biom14111434","article-title":"Evaluation of the efficacy of a full-spectrum Low-THC cannabis plant extract using in vitro models of inflammation and excitotoxicity","volume":"14","author":"Ross-Munro","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurot.2026.e01033_bib25","doi-asserted-by":"crossref","first-page":"434025","DOI":"10.3389\/fpls.2018.01969","article-title":"The case for the entourage effect and conventional breeding of clinical cannabis: no \"strain,\" no gain","volume":"9","author":"Russo","year":"2019","journal-title":"Front Plant Sci"},{"key":"10.1016\/j.neurot.2026.e01033_bib26","article-title":"Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in children with autism spectrum disorder","volume":"8","author":"El Sukkari","year":"2025","journal-title":"Adv Complement Alt Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01033_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/dmcn.15574","article-title":"Placebo effects in children with autism spectrum disorder","volume":"65","author":"Curie","year":"2023","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01033_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1573407214666180703130525","article-title":"Cannabis sativa L. constituents and their role in neuroinflammation","volume":"15","author":"Borgonetti","year":"2019","journal-title":"Curr Bioact Compd"},{"key":"10.1016\/j.neurot.2026.e01033_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3389\/fncel.2016.00294","article-title":"Cannabinoid receptors in the central nervous system: their signaling and roles in disease","volume":"10","author":"Kendall","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e01033_bib30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","article-title":"Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas","volume":"9","author":"Stella","year":"2010","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01033_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/pharmaceutics12030265","article-title":"Cannabinoids, blood\u2013brain barrier, and brain disposition","volume":"12","author":"Calapai","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01033_bib32","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/brain\/awg143","article-title":"Cannabis and the brain","volume":"126","author":"Iversen","year":"2003","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01033_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0165-6147(00)01805-8","article-title":"Modulation of transmitter release via presynaptic cannabinoid receptors","volume":"22","author":"Schlicker","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.neurot.2026.e01033_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108287","article-title":"Differential glutamatergic and GABAergic contributions to the tetrad effects of \u03949-tetrahydrocannabinol revealed by cell-type-specific reconstitution of the CB1 receptor","volume":"179","author":"De Giacomo","year":"2020","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01033_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70099","article-title":"CB1 receptor activation provides neuroprotection in an animal model of glutamate-induced excitotoxicity through a reduction of NOX-2 activity and oxidative stress","volume":"30","author":"Mart\u00ednez-Torres","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.neurot.2026.e01033_bib36","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.3390\/ijms23073861","article-title":"Autism spectrum disorder: focus on glutamatergic neurotransmission","volume":"23","author":"Montanari","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e01033_bib37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejphar.2018.07.039","article-title":"Endocannabinoid system, stress and HPA axis","volume":"834","author":"Micale","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01033_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2826.2008.01673.x","article-title":"The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity","volume":"20","author":"Cota","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.neurot.2026.e01033_bib39","article-title":"Cannabis and cannabinoid use in autism spectrum disorder: a systematic review","volume":"44","author":"Silva","year":"2021","journal-title":"Trends Psychiatr Psychother"},{"key":"10.1016\/j.neurot.2026.e01033_bib40","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-Enriched cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01033_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77175-y","article-title":"In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa","volume":"10","author":"Zagzoog","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurot.2026.e01033_bib42","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fimmu.2020.613613","article-title":"Cannabinoids as key regulators of inflammasome signaling: a current perspective","volume":"11","author":"Suryavanshi","year":"2021","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.neurot.2026.e01033_bib43","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1111\/bph.14019","article-title":"Tetrahydrocannabinolic acid is a potent PPAR\u03b3 agonist with neuroprotective activity","volume":"174","author":"Nadal","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.neurot.2026.e01033_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00828","article-title":"Medicinal cannabis plant extract (NTI164) modifies epigenetic, ribosomal, and immune pathways in paediatric acute-onset neuropsychiatric syndrome","author":"Keating","year":"2026","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2026.e01033_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fncel.2018.00078","article-title":"Epigenetics and autism spectrum disorder: is there a correlation?","volume":"12","author":"Eshraghi","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.neurot.2026.e01033_bib46","first-page":"1","article-title":"Full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) improves symptoms of Rett syndrome: an open-label study","author":"Keating","year":"2025","journal-title":"J Paediatr Child Health"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:09:24Z","timestamp":1790125764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926002035"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01033","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study)","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01033"}}